{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T20:54:44Z","timestamp":1768337684462,"version":"3.49.0"},"reference-count":0,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,10,2]],"date-time":"2003-10-02T00:00:00Z","timestamp":1065052800000},"content-version":"vor","delay-in-days":2314,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1997,6]]},"abstract":"<jats:p><jats:italic>Aims<\/jats:italic>\u2007To quantify the risk of serious blood and skin disorders requiring hospitalization among otherwise healthy users of co\u2010trimoxazole<\/jats:p><jats:p><jats:italic>Methods<\/jats:italic>\u2007We conducted a population\u2010based cohort study at Group Health Cooperative of Puget Sound (GHC).<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>\u2007During the years 1987 to 1993 we found six cases of co\u2010trimoxazole\u2010associated blood disorders and three cases of co\u2010trimoxazole\u2010associated skin disorders yielding risks of 5.6\/100,000 (95% CI 2.6\u201312.2) and 2.8\/100,000 (95% CI 0.9\u20138.2) respectively. In all cases found there was prompt recovery after discontinuation of co\u2010trimoxazole. We found no cases of toxic epidermal necrolysis.<\/jats:p><jats:p><jats:italic>Conclusions<\/jats:italic>\u2007We conclude that the risk of blood and skin disorders associated with the use of co\u2010trimoxazole leading to hospitalization is low.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1997.00590.x","type":"journal-article","created":{"date-parts":[[2003,10,14]],"date-time":"2003-10-14T17:01:11Z","timestamp":1066150871000},"page":"649-651","source":"Crossref","is-referenced-by-count":15,"title":["Hospitalization for serious blood and skin disorders following co\u2010trimoxazole"],"prefix":"10.1111","volume":"43","author":[{"given":"Marian","family":"Wald Myers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hershel","family":"Jick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,10,2]]},"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1997.00590.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1997.00590.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1997.00590.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T07:20:02Z","timestamp":1698391202000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1997.00590.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,6]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1997,6]]}},"alternative-id":["10.1046\/j.1365-2125.1997.00590.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1997.00590.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,6]]}}}